Shanghai Wellhope Pharmaceutical

Shanghai Wellhope Pharmaceutical is a Chinese pharmaceutical company specializing in the development and commercialization of botanical-based therapies, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the research of Erigeron breviscapus (Fleabane), a traditional Chinese medicinal herb, from which it extracts active compounds such as scutellarin. Its flagship product line, the Dengzhan Xinyang series, includes injections, capsules, and tablets widely used in clinical settings for treating stroke, paralysis, and coronary heart disease. Shanghai Wellhope integrates modern extraction and purification technologies with traditional herbal medicine to meet high-quality pharmaceutical standards. The company maintains a significant research and development presence in Shanghai and operates GMP-certified manufacturing facilities to support its commercial portfolio.